Paper35339668
Recent advances of nanodrug delivery system in the treatment of hematologic malignancies.
Ye Q and 4 others. Semin Cancer Biol, 2022. Cited by 20 papers, by iCite.
Cite this record
ConductScience Library. Recent advances of nanodrug delivery system in the treatment of hematologic malignancies. Papers, record 35339668. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/35339668
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Recent advances of nanodrug delivery system in the treatment of hematologic malignancies.
- PubMed
Topics5
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Hematologic Neoplasms | Major topic |
| Nanoparticles | Major topic |
| Humans | |
| Drug Delivery Systems | |
| Immunotherapy |
Source PubMed
Cited by8
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 20 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42269180 | Mitophagy-mediated immune evasion: Shared strategies of pathogens. | Redox Biol | 2026 | https://conductscience.org/library/papers/42269180 | PubMed |
| 41390419 | HPDA-based tubule-targeting nanoplatform alleviates oxidative stress and ferroptosis for the reversal of renal interstitial fibrosis. | J Nanobiotechnology | 2025 | https://conductscience.org/library/papers/41390419 | PubMed |
| 41127516 | Inflammation, diabetic foot and related treatments. | Front Endocrinol (Lausanne) | 2025 | https://conductscience.org/library/papers/41127516 | PubMed |
| 39679804 | Targeted Delivery of c(RGDfk)-Modified Liposomes to Bone Marrow Through In Vivo Hitchhiking Neutrophils for Multiple Myeloma Therapy. | Adv Sci (Weinh) | 2025 | https://conductscience.org/library/papers/39679804 | PubMed |
| 39043825 | A bispecific nanosystem activates endogenous natural killer cells in the bone marrow for haematologic malignancies therapy. | Nat Nanotechnol | 2024 | https://conductscience.org/library/papers/39043825 | PubMed |
| 37726283 | mRNA vaccines in disease prevention and treatment. | Signal Transduct Target Ther | 2023 | https://conductscience.org/library/papers/37726283 | PubMed |
| 37403095 | Advances in PD-1 signaling inhibition-based nano-delivery systems for tumor therapy. | J Nanobiotechnology | 2023 | https://conductscience.org/library/papers/37403095 | PubMed |
| 37323948 | Multifunctional Nanoplatform-Mediated Chemo-Photothermal Therapy Combines Immunogenic Cell Death with Checkpoint Blockade to Combat Triple-Negative Breast Cancer and Distant Metastasis. | Int J Nanomedicine | 2023 | https://conductscience.org/library/papers/37323948 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/35339668
GET https://conductscience.org/api/papers/v1/35339668/authors